Future Role Of Apoteksbolaget

8 January 1996

Along with its report on health care reform, the Swedish Parliamentary Commission presented an analysis of the activities of the state pharmacy corporation, Apoteksbolaget. The Commission has proposed that Apoteksbolaget's monopoly regarding retail trade with all prescription drugs and certain non-prescription medicines should be maintained in the interests of general safety and the protection of people's health and lives.

With regard to non-Rx drugs, it is proposed that these be divided into two groups; one refers to drugs allowed to be sold only through Apoteksbolaget and the other refers to over-the-counter medicines allowed to be distributed in retail channels outside Apoteksbolaget.

The report also proposes that county councils or hospitals which have a care management agreement with a county council will have the right to procure drugs directly from an approved wholesaler. In future, Apoteksbolaget will have a duty to supply all approved drugs in Sweden, and it should be wholly-owned by the state, it adds.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight